Fusion Pharmaceuticals Inc.
FUSNNASDAQHealthcare
$21.55
+$0.03(+0.14%)
Market Cap$1.8B
P/E Ratio—
52W High$21.6
52W Low$2.31
Fusion Pharmaceuticals Inc. (FUSN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FUSN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.07M | $1.46M | $1.44M | $0.00M | $0.00M |
| Cost of Revenue | $1.34M | $58.90M | $56.36M | $0.48M | $0.29M |
| Gross Profit | $0.72M | ($57.43M) | ($54.92M) | ($0.48M) | ($0.29M) |
| Gross Margin %(computed) | 34.96% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $68.76M | $58.90M | $56.36M | $17.19M | $10.63M |
| G&A Expenses | $31.20M | $30.60M | $27.10M | $20.74M | $7.59M |
| Total Operating Expenses | $99.95M | $89.50M | $83.45M | $37.94M | $18.04M |
| Operating Income | ($99.23M) | ($88.03M) | ($82.02M) | ($37.94M) | ($18.22M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $9.53M | $2.16M | $0.38M | $0.33M | $0.58M |
| Interest Expense | $5.17M | $1.80M | $0.00M | $0.33M | $0.00M |
| Income Before Tax | ($94.11M) | ($89.45M) | ($81.17M) | ($75.72M) | ($15.94M) |
| Income Tax Expense | $0.79M | ($1.84M) | ($0.12M) | $2.61M | $0.25M |
| Net Income | ($94.90M) | ($87.61M) | ($81.05M) | ($78.33M) | ($16.19M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.45 | $-2.00 | $-1.90 | $-3.56 | $-0.10 |
| Wtd Avg Shares | 65.61M | 43.75M | 42.60M | 22.03M | 155.71M |
| EBITDA | ($87.60M) | ($87.26M) | ($81.38M) | ($31.05M) | ($17.75M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Fusion Pharmaceuticals Inc. data
About Fusion Pharmaceuticals Inc. (FUSN) Income Statement
Fusion Pharmaceuticals Inc. (FUSN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, FUSN reported revenue of $0.00B, gross profit of $0.00B (gross margin 34.96%), and net income of ($0.09B) — a net profit margin of -4588.83%.
Frequently asked questions
FUSN · 4 questionsFusion Pharmaceuticals Inc. (FUSN) reported revenue of $0.00B for 2023, up 41.5% year-over-year.
FUSN revenueFUSN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08